原发性肝细胞肝癌合并胆栓临床诊断与治疗进展

Primary hepatocellular carcinoma with biliary clinical diagnosis and treatment of cork

原发性肝细胞癌伴胆管癌栓（hepatocellular carcinoma with bile duct tumor thrombi，HCCBDT）是胆道系统最常见的继发性肿瘤，其主要以肝细胞癌向胆道系统转移所致梗阻性黄疸为特点，肝细胞肝癌合并胆管癌栓的发病率不到原发性肝细胞癌患者的10％．尸检发现其发生率为1．2％～9．0％。虽然原发性肝细胞癌合并胆管癌栓发病率低，但由于我国人口基数较大，致使患者绝对数量也较大，发病人数每年超过10000人。以往通常认为肝癌出现黄疸症状已属肝癌晚期的表现，导致人们对肝细胞肝癌合并胆管癌检多采取保守治疗或消极态度，缺乏根治的方法，致使很大一部分原发性肝细胞癌合并胆管癌栓病人丧失治疗机会，预后较差。近年来，随着外科领域的不断进步，发现原发性肝癌合并胆管癌栓其实并非肝癌的晚期表现。

HCC with bile duct bolt （hepatocellular carcinoma with bile duct tumor thrombi, HCCBDT） is the most common secondary biliary system tumors, which mainly due to the metastasis to the hiliary system is characterized by obstructive jaundice, 10% incidence of hepatocellular carcinoma with BDT is less than HCC patients [1], the autopsy found that the incidence rate of 1.2% to 9.0% [2]. Although the primary hepatocellular carcinoma with low incidence of BDT, but because of the larger population base, resulting in the absolute number of patients is larger, the number of cases each year more than 10,000 people. Hepatocellular jaundice in the past generally considered already advanced liver cancer symptoms performance, led people to hepatocellular carcinoma with BDT to take a more conservative treatment or negative attitudes, lack of radical method, resulting in a large part of primary hepatocellular carcinoma with cholangiocarcinoma Suppository patients lose access to treatment, the prognosis is poor. In recent years, advances in the surgical field, find primary hepatocellular carcinoma with BDT in fact not the late performance of liver cancer.